Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) shares dropped 1.8% during mid-day trading on Monday . The company traded as low as $4.41 and last traded at $4.41, with a volume of 499,004 shares trading hands. The stock had previously closed at $4.49.

TTPH has been the topic of a number of recent research reports. BMO Capital Markets initiated coverage on shares of Tetraphase Pharmaceuticals in a report on Monday, April 11th. They issued a “market perform” rating and a $8.00 target price on the stock. Wedbush restated a “neutral” rating and issued a $11.00 target price (up from $8.00) on shares of Tetraphase Pharmaceuticals in a report on Thursday, May 5th. Gabelli lowered shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $7.00 target price on the stock. in a report on Friday, May 13th. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Saturday, May 14th. Finally, Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a report on Wednesday, July 6th. Eleven analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Tetraphase Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $20.80.

The stock has a 50 day moving average price of $4.19 and a 200-day moving average price of $4.93. The firm’s market capitalization is $161.43 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by $0.02. The firm earned $2 million during the quarter, compared to analyst estimates of $2.20 million. The company’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.66) EPS. On average, analysts expect that Tetraphase Pharmaceuticals Inc. will post ($1.96) earnings per share for the current year.

A hedge fund recently raised its stake in Tetraphase Pharmaceuticals stock. California Public Employees Retirement System boosted its position in shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 1,459.3% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 276,000 shares of the biopharmaceutical company’s stock after buying an additional 258,300 shares during the period. California Public Employees Retirement System owned about 0.76% of Tetraphase Pharmaceuticals worth $2,768,000 as of its most recent SEC filing.

Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.